消息面上，基石药业近日宣布，公司RET抑制剂普吉华(普拉替尼胶囊，100mg)被成功纳入中国国家医 疗保障局公布的最新版《国家基本医疗保险、生育保险和工伤保险药品目录》，该目录将于2026年1月1 日起正式实施。截至目前，基石药业已成功推进4款创新药获批上市，其中3款由基石药业在中国完成临 床试验及注册获批上市的产品，已被纳入国家医保目录。 天风证券（601162）今年8月发布的研报指出，预计普拉替尼纳入医保后有望加速放量。基石药业的临 床前管线包括多特异性抗体、ADC等超过九个潜在候选药物，专注于FIC/BIC研究，涵盖肿瘤学、自身 免疫和炎症性疾病等多个治疗领域。公司创新的内部ADC技术平台，以优化专有连接子为特色，改善 肿瘤选择性有效载荷的释放。平台支持管线2.0多个ADC产品，有望为公司未来发展提供持续动力。 基石药业-B(02616)涨超5%，截至发稿，涨5.57%，报6.07港元，成交额2270.42万港元。 ...

Group 1 - The stock of Basilea Pharmaceutica Ltd. (02616) increased by over 8%, reaching HKD 8.74 with a trading volume of HKD 11.72 million [1] - Singapore's Government Investment Corporation (GIC Private Limited) increased its stake in Basilea by acquiring 80.4 million shares at an average price of HKD 7.90 per share, totaling approximately HKD 635 million, resulting in a new holding of 5.49% [1] - Basilea reported a significant decline in revenue for the first half of the year, amounting to RMB 49.45 million, a decrease of 80.54% year-on-year, while R&D expenses rose by 58.75% to RMB 105 million, leading to a loss of RMB 270 million [1] Group 2 - Basilea's preclinical pipeline includes over nine potential candidates, focusing on FIC/BIC research across oncology, autoimmune, and inflammatory diseases [2] - The company has developed an innovative internal ADC technology platform that enhances the release of payloads selectively targeting tumors, supporting multiple ADC products in its pipeline [2] - The platform is expected to provide ongoing momentum for the company's future development [2]